

# PRESS RELEASE

**HANSA**  
BIOPHARMA



## Hansa Biopharma announces participation in Fall conferences and an updated financial calendar

Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020.

Hansa Biopharma will host a Capital Markets Day event on October 29, 2020 in Copenhagen as a combined virtual/physical setup.

**Lund, Sweden August 31, 2020.** Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the following upcoming investor conferences in September:

- Pareto Securities Health Care Conference on Thursday September 3, 2020, at 15:30 CET
- Citibank's Annual BioPharma Virtual Conference on Wednesday September 9, 2020
- H.C.Wainwright Healthcare Conference on Tuesday September 15, 2020
- Bank of America Merrill Lynch Healthcare Conference on Wednesday September 16, 2020
- MorganStanley Global Healthcare Conference on Friday September 18, 2020 at 8:00am EST/14:00 CET
- ABG Small & Midcap Seminar, Copenhagen on Wednesday September 23, 2020 at 13:30 CET

A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at [www.hansabiopharma.com](http://www.hansabiopharma.com).

### Calendar

Aug 31, 2020	Kempen Road Show, Tel Aviv/Paris/Benelux (virtual)
Sep 3, 2020	Pareto Healthcare Conference, Stockholm (virtual)
Sep 9, 2020	Citibank's Annual BioPharma Virtual Conference, Boston (virtual)
Sep 15, 2020	H.C. Wainwright Healthcare Conference, NYC (virtual)
Sep 16, 2020	Bank of America Merrill Lynch Healthcare Conf., London (virtual)
Sep 18, 2020	MorganStanley Global Healthcare Conference, NYC (virtual)
Sep 23, 2020	ABG Small & Mid Cap Seminar, Copenhagen and virtual
Oct 22, 2020	Interim Report Jan-Sep 2020
Oct 29, 2020	Hansa Biopharma Capital Markets Day, Copenhagen and virtual
Nov 17, 2020	Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020	Jefferies Healthcare Conference, London
Nov 25, 2020	Ökonomisk Ugebrev Life Science Conference, Copenhagen
Feb 2, 2021	Interim report for Jan - Dec 2020
April 8, 2021	Annual Report 2020
April 22, 2021	Interim report for Jan - Mar 2021
July 15, 2021	Interim report for Jan - Jun 2021
Oct 21, 2021	Interim report for Jan - Sep 2021

The information was submitted for publication, through the contact person set out below, at 08:00 a.m. (CET) on August 31, 2020.

#### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709-298 269  
E: klaus.sindahl@hansabiopharma.com

Katja Margell  
Head of Corporate Communications  
Hansa Biopharma  
M: +46 (0) 768-198 326  
E: katja.margell@hansabiopharma.com

#### About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product candidate, imlifidase, is an antibodycleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.

Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020.

Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HNSA  
ISIN: SE 0002148817